![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 24, 2020 1:38:00 AM
1. WHY THE ADSORBER IS A GIFT FOR PATIENTS, SURGEONS AND CLINICS?
The guys from the Asklepios clinics in Germany LOVE the adsorber because of two reasons:
1. it DRASTICALLY improves patient safety
2. it substantially improves the overall throughput times of patients
Throughput times are critical in Europe in terms of profit numbers.
Background: each indication / treatment is reimbursed with a fixed amount called "Fallpauschale" in Germany (flat rate or lump compensation). If you are interested in profits, and Asklepios is quite "famous" for that and aim for ROIs of 12 - 15 %, it is crucial for them to get rid off the patients asap and not lose any time with complications.
I do not know about the US but to my knowledge this should apply to more or less all clinics in Europe: you only make serious money if you keep complications to a minimum and improve throughput times as much as you can.
2. WHY ARE THESE BLOOD THINNERS ABSOLUTE BLOCKBUSTERS FOR ASTRAZENECA AND BAYER?
By far most people around the world tend to mess up their arteries by just eating meat and consuming dairy products (please check out the documentary Game Changers -
If you mess up your arteries you will pay for that with severe cardiac issues (and a highly increased risk of Alzheimer) later on in your life. The common solution to reduce your cardiac issues and overall stroke risk then is to constantly take blood thinners.
However, the price these people pay for taking blood thinners: in case of any emergency surgery (not only cardiac) the surgeons will be in sweat because of all sort of bleeding issues.
Please note that with either Ticagrelor or Rivaroxaban you should wait AT LEAST 5 days (studies show that 10 - 12 days would be ideal) to not run in increased bleeding risks in surgery. Of course in emergency situations this is not always possible. AND - as we learned above - waiting times respectively messed up throughput times will ruin overall hospital profits.
Is all of this limited to only cardiac surgery? No. The bleeding issue is a topic in all emergency like situation for patients using blood thinners.
3. WHAT ABOUT THE PATENTS RUNNING OUT FOR BAYER AND ASTRAZENECA?
Does not make a difference at all for CTSO. As long as Ticagrelor or Rivaroxaban will be used as blood thinners and as long as CTSO is THE SOLUTION to wash out this stuff in under 2 hours in context of any surgery this will mean:
a. SERIOUS REVENUES for CTSO
b. less sweaty surgeons
c. increased patient safety
d. improved throughput times of patients and higher profits for clinics
This will apply for as long as not all people turn into vegans and stop messing up their arteries and has nothing to do with expiring patents.
THIS IS HUGE!
Recent CTSO News
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- CytoSorbents Announces the Launch and Immediate Availability of the PuriFi™ Blood Pump in the European Union • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:31:20 PM
- CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM